TopgOptions

AEZS European approval to market Macrillen

Pembelian
NASDAQ:AEZS   Aeterna Zentaris Inc.
AEterna has a variety of new products in its pipeline.
Macrilen, for example, is the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency.

AEterna received European approval to market Macrillen.

Dr. Christian Strasburger: "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition.”

I think AEZS is a sleeping giant.

My price target is $1.25.

Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.